Retinai

What Retinai does

RetinAI (legally Ikerian AG) is a Swiss health technology company founded in 2017 in Bern that develops AI-powered software for ophthalmic image analysis and medical data management. Its flagship product, the RetinAI Discovery platform, is a vendor-neutral, cloud-based system that ingests multi-modal imaging data — including OCT, fundus, and fundus autofluorescence — from any device in DICOM or proprietary formats (JPEG, PNG, TIFF, PDFs), applies proprietary computer-vision AI to extract biomarkers for retinal diseases such as AMD, diabetic retinopathy, DME, glaucoma, and geographic atrophy, and supports multi-center collaboration through real-time, secure cloud access. Discovery is offered as a platform-plus-modules architecture with sub-products including Discovery UNITY, Discovery for Clinical Studies, Discovery for Clinics, Discovery CONNECT, Real World Evidence, and Precision Medicine.

The company's AI portfolio includes the CE-marked RetinAI OCT Atlas® (a single algorithm covering AMD, DR, DME, and Glaucoma), the CE-MDR-certified LuxIA® diabetic retinopathy screening algorithm co-developed with FVS, and 30+ additional CE-marked and Research Use Only biomarkers spanning ophthalmology, neurodegenerative, and vascular indications. Capabilities include layer and fluid segmentation, biomarker detection (drusen, hyper-reflective foci, geographic atrophy, epiretinal membrane, reticular pseudodrusen, and others), disease progression prediction, and natural-language patient cohort search. The platform has processed approximately 1 million patient images and is cited in over 40 peer-reviewed publications.

RetinAI serves three primary customer segments: pharmaceutical and life sciences companies (including Novartis, Boehringer Ingelheim, Isarna Therapeutics, and OcuTerra Therapeutics), eye clinics and hospitals, and academic and clinical researchers. Revenue is generated through enterprise SaaS subscriptions for pharma and clinical deployment, usage-based credit pricing for disease evaluation apps distributed via Heidelberg Engineering's AppWay marketplace, and direct enterprise field sales. Commercial channels include a strategic distribution agreement with Sanoptis across European ophthalmology clinics (tied to the Series B lead investment) and the Heidelberg AppWay device-integrated marketplace. The company holds EU-MDR Class IIa registration, FDA 510(k) clearance, ISO 13485 certification, and compliance with HIPAA, GDPR, PIPEDA, and 21 CFR Part 11. In October 2025, RetinAI was acquired by EssilorLuxottica, the global eyewear and eye-care corporation.

Name

Retinai

Legal name

Ikerian AG

Website

https://retinai.com

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

11–50 employees

Short description

RetinAI (Ikerian AG) develops AI-powered ophthalmology software via its Discovery platform, serving pharmaceutical companies, eye clinics, and academic researchers with CE-marked and FDA-cleared AI biomarkers for retinal disease analysis, clinical trials, and real-world evidence generation.

Ownership category

akta.pro rank

Product category

Ophthalmology AI Software

NAICS

Ophthalmic Goods Manufacturing (339115), Diagnostic Imaging Centers (621512)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

akta.pro secondary industries

Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN), Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Ophthalmic imaging software
• AI biomarker analysis
• Medical image management
• Retinal disease detection
• Clinical trial data platform

Headquarters

HQ city

Bern

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. SaaS Platform Subscription (Discovery): Discovery platform is offered as a cloud-based SaaS subscription to pharma companies, clinics, hospitals, and academic researchers. Subscription provides access to the platform, AI models, data management tools, and collaboration features. Pricing varies by customer segment (pharma/life sciences vs. clinics) and usage scope.
2. Disease Evaluation Apps (Credit-based Usage): Disease evaluation apps accessed via Heidelberg AppWay use a credit-based consumption model. Reports are priced per credit (1 credit for nAMD, dAMD, DR/DME, CME; 3 credits for GA reports). Credits are purchased in bundles (100 to 2,000+), with volume-based pricing that decreases cost per credit at higher tiers. A subscription provides access to all available apps.
3. Pharma & Life Sciences Enterprise Contracts: Direct enterprise contracts with pharmaceutical companies for use in clinical trials and real-world evidence generation. These contracts are typically multi-year, potentially including professional services for platform configuration, data integration, and study-specific customization.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

Core offering

RetinAI provides RetinAI Discovery®, an AI-powered medical image and data management platform for ophthalmology that enables healthcare professionals and pharmaceutical companies to ingest, harmonize, and analyze multi-modal retinal imaging (OCT, fundus, FAF) using proprietary CE-marked and FDA-cleared AI models. The platform delivers automated biomarker extraction, real-world evidence generation, and multi-center clinical study workflows for ophthalmic indications including AMD, DR, DME, glaucoma, and geographic atrophy. Standalone AI algorithms (RetinAI OCT Atlas® and LuxIA®) and credit-based Disease Evaluation Apps distributed via Heidelberg AppWay complement the core platform.

Product overview

RetinAI offers a platform-plus-modules architecture centered on the Discovery® platform, a standalone medical image and data management system for ophthalmology. The core platform integrates with specialized modules: Discovery UNITY (disease understanding/R&D), Discovery for Clinical Studies (multi-vendor data management for trials), Discovery for Clinics (clinical workflow intelligence), Discovery CONNECT (data connectivity), Real World Evidence (population insights), and Precision Medicine (personalized treatment). The company also provides Disease Evaluation Apps accessible via Heidelberg AppWay, and AI models including the CE-marked RetinAI OCT Atlas® (covering AMD, DR, DME, Glaucoma) and LuxIA® (diabetic retinopathy screening). The platform supports pharmaceutical companies, clinics/hospitals, clinical researchers, and academic AI researchers.

Differentiator

Problem solved

Functional benefit

Products and services

• RetinAI Discovery® Standalone medical image and data management platform for healthcare professionals and pharmaceutical companies to manage data, gain enhanced insights with automatic AI analysis, and supercharge clinical and research workflows in ophthalmology. The platform ingests DICOM-compliant and proprietary formats (OCT, fundus, FAF, PDFs, JPEG, PNG, TIFF), supports multi-modal imaging, and provides automated biomarker extraction, real-time collaboration, and regulatory-compliant data handling.
• RetinAI OCT Atlas® CE-marked AI algorithm for automated clinical analysis of OCT volumes covering age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), and glaucoma in a single unified model. Provides layer and fluid segmentation across retinal structures for clinical use in the EU. AI modules for biomarkers, fluid, and layer segmentation are designated Research Use Only (RUO) in the US.
• LuxIA® Diabetic Retinopathy Screening Algorithm CE-MDR certified AI-based diabetic retinopathy screening algorithm co-developed with FVS, approved for clinical use in Europe for automated DR screening from retinal images. Designed for deployment in diabetic eye disease screening programs and clinical workflows.
• Disease Evaluation Apps Expert-level AI analysis apps distributed via Heidelberg Engineering's AppWay marketplace within HEYEX 2, providing automated OCT analysis and PDF reports during patient visits for retinal disease management. Apps cover nAMD, dAMD, DR/DME, CME, and GA with CE-marked AI models. Pricing is credit-based: 1 credit per standard report, 3 credits per GA report; credit bundles range from 100 credits (€50) to 2,000 credits (€500).

Quantifiable outcome

• 30+ CE-marked and research use only biomarkers across ophthalmology, neurodegenerative, vascular, and rare disease areas
• +3 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability8 records

Feature10 records

Partnerships

Ten partnerships are on record, tiered flagship and core.

• EssilorLuxotticaflagshipOthers · 16 October 2025EssilorLuxottica acquired Ikerian AG (operating as RetinAI) in October 2025. This acquisition strengthens EssilorLuxottica's medical technology portfolio with AI-powered analytics capabilities added to its existing eye care, diagnostics, and surgical ecosystem. The acquisition aligns with EssilorLuxottica's strategy to build a digitally enabled patient journey in eye care and follows its December acquisition of Italian company Espansione Group.
• FVScoreStrategic or Co-development Partner · 30 April 2025RetinAI and FVS co-developed the LuxIA AI-based diabetic retinopathy screening algorithm, which received CE-MDR certification in April 2025. The co-development partnership combined RetinAI's AI expertise in retinal image analysis with FVS's domain knowledge in diabetic eye disease, resulting in a certified screening tool for clinical use in European clinics.
• SanoptiscoreChannel Partner/ Reseller/ Distributor · 16 October 2024Sanoptis led RetinAI's USD 8 million Series B funding round and simultaneously entered a commercial agreement to distribute RetinAI Discovery across its European ophthalmology clinic network. This dual financial and commercial partnership is the company's most significant go-to-market relationship, combining capital investment with guaranteed distribution reach across European markets. Sanoptis' network spans multiple European countries, providing immediate market access for RetinAI's clinical and AI solutions.
• MAXOcoreStrategic or Co-development Partner · 9 September 2024RetinAI partnered with MAXO to advance clinical studies in dry eye disease. The collaboration leverages RetinAI's imaging and data management capabilities combined with MAXO's therapeutic development expertise to support clinical research workflows and data analysis in ocular surface disease.
• Stephen J. Ryan Initiative for Macular Research (RIMR) AMD ConsortiumcoreStrategic or Co-development Partner · 29 November 2023RetinAI joined the RIMR AMD Consortium to build a global retinal imaging initiative targeting research in age-related macular degeneration. The partnership leverages Discovery platform to standardize and analyze retinal imaging data across the consortium's international research network, accelerating AMD biomarker discovery and validation.
• Retina Consultants of AmericacoreStrategic or Co-development Partner · 25 July 2023RetinAI and Retina Consultants of America partnered to build the most comprehensive U.S.-based real-world evidence database in ophthalmology. The partnership leverages Discovery platform to aggregate multi-site retinal imaging data from across Retina Consultants of America's network of practices, enabling large-scale real-world evidence generation for research, drug development, and clinical outcomes analysis.
• Boehringer IngelheimcoreStrategic or Co-development Partner · 21 April 2023RetinAI partnered with Boehringer Ingelheim to advance novel treatments for patients with geographic atrophy using artificial intelligence. Discovery platform is used to generate comprehensive disease insights from imaging data to support Boehringer Ingelheim's clinical development program for GA, a leading cause of blindness. This partnership demonstrates RetinAI's utility as a clinical trial data partner for major pharmaceutical companies.
• Geographic Atrophy Expert Working GroupcoreStrategic or Co-development Partner · 17 April 2023RetinAI partnered with the GA Expert Working Group to enable data collaboration and automated analysis of GA biomarkers for CAM (Classification of Atrophy Meeting) using Discovery platform. The partnership focuses on standardized analysis of GA imaging biomarkers across longitudinal datasets to support consensus-building on new GA biomarkers and disease definitions.
• Classification of Atrophy Meeting (CAM) GroupcoreStrategic or Co-development Partner · 1 December 2022RetinAI partnered with the Classification of Atrophy Meeting (CAM) Group — a consortium of 30+ international GA experts — in December 2022 to provide Discovery platform for peer-to-peer data collaboration and automated biomarker analysis of real-world GA patient datasets. Discovery and its GA segmentation models were featured at CAM 8 (Feb 2023) and CAM 9 (Sept 2023) scientific meetings. The partnership enables the expert working group to analyze longitudinal multi-modal OCT and FAF imaging data at scale using AI.
• Heidelberg EngineeringcoreTechnology or IntegrationRetinAI's Disease Evaluation Apps are integrated with Heidelberg Engineering's HEYEX 2 system via the AppWay secure data transfer portal. This integration embeds RetinAI's AI analysis directly into the Heidelberg imaging workflow, enabling expert-level OCT analysis to be accessed by clinics using Heidelberg devices during routine patient visits. Distribution via AppWay uses a credit-based pricing model.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• VoxelCloud: VoxelCloud develops AI-based medical image analysis across multiple specialties, including ophthalmology, and is an emerging player with overlapping capabilities in retinal disease detection and clinical decision support.

Direct peers

• AEYE Health: AEYE Health develops FDA-cleared AI for autonomous diabetic retinopathy screening from retinal images, directly competing with RetinAI's LuxIA DR screening algorithm and OCT analysis capabilities in primary care and clinic settings.
• Eyenuk: Eyenuk offers FDA-cleared EyeArt AI for autonomous DR screening, competing head-to-head with RetinAI's screening-focused algorithms and serving a similar clinic, payor, and pharma customer base.
• Digital Diagnostics: Digital Diagnostics pioneered the first FDA-authorized autonomous AI diagnostic system (IDx-DR) for diabetic retinopathy, competing with RetinAI's LuxIA and broader ophthalmic AI portfolio in clinical screening and primary care.
• iHealthScreen: iHealthScreen provides AI-based DR screening and risk assessment tools approved for clinical use, overlapping with RetinAI's disease evaluation apps and screening-focused algorithms.

Broad incumbents

• Heidelberg Engineering: Heidelberg is a leading OCT device manufacturer whose HEYEX 2 / AppWay platform already hosts RetinAI's disease evaluation apps. As a broad incumbent, Heidelberg is both a key channel partner and a potential competitor as it builds native AI into its imaging suite.
• Topcon Healthcare: Topcon is a major ophthalmic device manufacturer and a RetinAI investor (THINC Ventures) whose devices generate the imaging data RetinAI analyzes. It is both a strategic partner and a potential vertical competitor in ophthalmic AI.
• Carl Zeiss Meditec: Carl Zeiss Meditec is a global leader in ophthalmic diagnostics and surgical devices, integrating AI-driven analysis into its imaging platforms. As a broad incumbent, it competes with RetinAI for AI-driven workflow adoption in retina and glaucoma.
• Tempus: Tempus is a leader in clinical and real-world evidence generation in oncology and beyond, and has expanded into ophthalmology imaging AI. It overlaps with RetinAI's pharma-focused RWE and clinical study offerings as a broad incumbent in the data layer.
• Flatiron Health: Flatiron Health is a leading real-world evidence platform for oncology with expansion into broader therapeutic areas. It is comparable to RetinAI as a pharma-facing RWE and clinical data partner, albeit at much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/retin_ai
• LinkedInlinkedin.com/company/retinai
• Facebookfacebook.com/retinai

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Retinai